Essoras is a preclinical-stage biotech focused on developing next-generation molecular glue for RAS-addicted cancer, which is the most common genetic driver of cancer. Backed by Essor Capital and its management team that have decades of preclinical and early clinical phase development experience, Essoras is dedicated to advancing its leading asset, SP09253, into clinical trials by 2026. Bsed on its favorable pharmacological and pharmacokinetic profile, we expect SP09253 to become the best-in-class pan-RAS treatment. We are currently seeking global licensing and co-development opportunities for this asset.